Detail View

L-Type Ca2+ Channel Inhibition Rescues the LPS-Induced Neuroinflammatory Response and Impairments in Spatial Memory and Dendritic Spine Formation
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

Title
L-Type Ca2+ Channel Inhibition Rescues the LPS-Induced Neuroinflammatory Response and Impairments in Spatial Memory and Dendritic Spine Formation
Issued Date
2022-11
Citation
Kim, Jieun. (2022-11). L-Type Ca2+ Channel Inhibition Rescues the LPS-Induced Neuroinflammatory Response and Impairments in Spatial Memory and Dendritic Spine Formation. International Journal of Molecular Sciences, 23(21). doi: 10.3390/ijms232113606
Type
Article
Author Keywords
felodipineLPSgliosisneuroinflammationCa2+ channel blockerspatial memory
Keywords
CALCIUM-SENSING RECEPTORLONG-TERM POTENTIATIONTHERAPEUTIC TARGETSSIGNAL-TRANSDUCTIONION CHANNELSMICROGLIAACTIVATIONINFLAMMATIONMECHANISMSFELODIPINE
ISSN
1661-6596
Abstract
Ca2+ signaling is implicated in the transition between microglial surveillance and activation. Several L-type Ca2+ channel blockers (CCBs) have been shown to ameliorate neuroinflammation by modulating microglial activity. In this study, we examined the effects of the L-type CCB felodipine on LPS-mediated proinflammatory responses. We found that felodipine treatment significantly diminished LPS-evoked proinflammatory cytokine levels in BV2 microglial cells in an L-type Ca2+ channel-dependent manner. In addition, felodipine leads to the inhibition of TLR4/AKT/STAT3 signaling in BV2 microglial cells. We further examined the effects of felodipine on LPS-stimulated neuroinflammation in vivo and found that daily administration (3 or 7 days, i.p.) significantly reduced LPS-mediated gliosis and COX-2 and IL-1β levels in C57BL/6 (wild-type) mice. Moreover, felodipine administration significantly reduced chronic neuroinflammation-induced spatial memory impairment, dendritic spine number, and microgliosis in C57BL/6 mice. Taken together, our results suggest that the L-type CCB felodipine could be repurposed for the treatment of neuroinflammation/cognitive function-associated diseases. © 2022 by the authors.
URI
http://hdl.handle.net/20.500.11750/17468
DOI
10.3390/ijms232113606
Publisher
MDPI
Show Full Item Record

File Downloads

  • There are no files associated with this item.

공유

qrcode
공유하기

Total Views & Downloads